Photo of Marshall Posner

Marshall Posner

  • PROFESSOR Medicine, Hematology and Medical Oncology
  • PROFESSOR Otolaryngology
Print ProfilePrint Profile


  • Medical Oncology

  • American Board of Internal Medicine

Clinical Focus

  • Adenoid Cystic Carcinoma (ACC)
  • Clinical Trials
  • Gum Cancer
  • HPV Related Oropharynx, Tongue Or Tonsil Cancer
  • Head and Neck Cancers
  • Immunotherapy
  • Merkel Cell Tumors
  • Mouth Cancer
  • Nasal Cavity Cancer
  • Nasopharyngeal Cancer (NPC)
  • Oral Cavity Cancer
  • Oropharynx Cancer
  • Paranasal Sinus Cancer
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Pharynx Cancer
  • Photodynamic Therapy
  • Salivaery Ductal Carcinoma (SDC)
  • Salivary Gland Tumors
  • Sinus Cancer
  • Skull Base Tumors
  • Squamous Cell Carcinoma
  • Throat Cancer
  • Thyroid Cancer
  • Thyroid Tumors
  • Tonsil Cancer
  • Vaccines


  • MD, Tufts University

  • Residency, Internal Medicine
    Boston City Hospital

  • Fellowship, Medical Oncology
    Dana Farber Cancer Institute


    Dr. Marshall Posner is a Professor of Medicine and Director of the Human Monoclonal Antibody Laboratory in the Department of Cell and Gene Therapy at Mount Sinai School of Medicine. He is also Medical Director of the Head and Neck Oncology Center at the Mount Sinai Medical Center, and Medical Director of the Clinical Trials Office for the Tisch Cancer Institute.  Dr. Posner has been an advocate for clinical research and multi-disciplinary care in head and neck cancer. He has and continues to participate in international symposia and on planning committees devoted to advancing clinical care and directing clinical research in head and neck cancer.
    He is a current or past member of the editorial boards of many journals, including the Journal of Clinical Oncology, Annals of Oncology, Oral Oncology, The Oncologist, and Head and Neck, and he serves as an ad hoc reviewer for, among others, The New England Journal of Medicine. Dr. Posner has been a member of the National Institutes of Health Review Committees for the NIH Inter-Institute Program and the Specialized Programs of Research Excellence in Human Cancer, Head & Neck Cancer, and of the National Cancer Institute's Special Emphasis Panel for phase II Contracts. He has published over 190 peer-reviewed basic laboratory and clinical studies, as well as multiple reviews and abstracts.

    In the News:
    Dr. Posner discusses HPV-related oral cancer in the New York Times.

    Dr. Posner discusses the warning signs of oral cancer and what to watch out for on the Katie Couric show.

    The ASCO Post features Dr. Posner discussing "Challenges, Progress, and Future Directions in Head and Neck Cancer" (March 1, 2012)

    Dr. Marshall Posner discusses the link between HPV and oropharyngeal cancers in The Daily News feature The Daily Check Up.


  • 2007 -
    Ninth Warton Visiting Professor, Prince Margaret Hospital

  • 2007 -
    Tisch Award for Clinical Research, Dana-Farber Cancer Institute

  • 1975 -
    Alpha Omega Alpha, Medical Honor Society


Clinical Studies in Head and Neck Cancer

Development of curative therapeutics for patients with HPV positive and negative head and neck cancer, through clinical trials, drug development and translational studies using conventional chemotherapy, novel biotherapeutics vaccines and gene therapies.

HPV and Human Oropharyngeal Cancer

Translational studies to understand the biology and immunology of HPV related oropharyngeal cancer in order to inform therapeutic and preventative therapies in this disease.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Posner during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.


  • CEL-SCI; Eisai Inc.; Merck Serono

Royalty Payments:

  • sanofi-aventis

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Promedior

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Insurance Information

Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.

Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.

Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.

Edit profile in Sinai Central

Ruttenberg Treatment Center

1470 Madison Avenue
3rd floor
New York, NY 10029

Tel: 212-241-6756
Fax: 212-241-5599
Get Directions

Office Hours:
  • Monday 9:00am - 5:00pm
  • Tuesday 9:00am - 5:00pm
  • Wednesday 9:00am - 5:00pm
  • Thursday 9:00am - 5:00pm
  • Friday 9:00am - 5:00pm
Insurance Plans
  • 1199
  • Access Meicare
  • Aetna
  • Affinity
  • Amerigroup
  • AmidaCare
  • Cigna
  • Empire Blue Cross/Blue Shield
  • Fidelis
  • GHI
  • Health Insurance Plan (HIP)
  • HealthFirst
  • Healthfirst
  • Humana
  • Island Group
  • Magnacare
  • Medicaid of New York
  • Medicare
  • MetroPlus Health Plan
  • MultiPlan, Inc.
  • Oxford Health Plans
  • United Healthcare
  • VNS Medicare
  • WellCare of New York, Inc.
Payment Methods
  • Master Card
  • Visa
  • American Express
  • Discover
  • Personal Check
  • Cash